Ipsen Pharma SA

Ipsen’s Sohonos has a specific selectivity for the gamma subtype of retinoic acid receptors. Credit: Ipsen Pharma. Ipsen has received approval from the US Food and Drug Administration (FDA) for its Sohonos (palovarotene) capsules to treat people with the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP). It is approved as a retinoid to reduce the volume of new heterotopic ossification in adults and paediatric patients. Female patients must be eight years old and above to receive the treatment, and males must be at least ten. Recommended Reports Reports LOA and PTSR Model - Naratuximab Emtansine in Follicular Lymphoma GlobalData Reports LOA and PTSR Model - Saracatinib Difumarate in Fibrodysplasia Ossificans Progressiva (Myositis Os... GlobalData View all Companies Intelligence Ipsen SA View all The oral medicine Sohonos has a specific selectivity for the gamma subtype of retinoic acid receptors, which are skeletal development and ectopic bone regulators in the retinoid signalling pathway. Sohonos mediates the interactions between the receptors, growth factors and proteins, and lowers the formation of new abnormal bone in FOP sufferers. The FDA approval is based on the pivotal safety and efficacy data from the Phase III multicentre, open-label MOVE study in adult and paediatric patients. This included 107 patients who were administered oral palovarotene and compared with untreated individuals from the Ipsen worldwide FOP natural history study. The study showed that palovarotene successfully decreased the yearly volume of heterotopic ossification compared to no treatment beyond standard care. Ipsen research and development head Howard Mayer stated: ” Developing medicines for rare diseases takes commitment and belief from everyone involved. “We at Ipsen are sincerely grateful to the FOP community of patients and medical experts, as the first-ever treatment in the US for managing FOP would not be possible without their participation in the clinical trials and ongoing support.”

Ipsen’s palovarotene is intended to treat fibrodysplasia ossificans progressiva. Credit: Ipsen Pharma. The European Commission (EC) has refused to grant marketing authorisation for Ipsen’s investigational therapy , palovarotene, intended to treat fibrodysplasia ossificans progressiva (FOP). The EC’s decision comes after the Committee for Medicinal Products for Human Use (CHMP) provided a negative opinion in May 2023. Recommended Reports Reports Nitric Oxide Synthase (NO Synthase or NOS or EC 1.14.13.39) Drugs in Development by Therapy Areas... GlobalData Reports LOA and PTSR Model - Non-Disclosed GlobalData View all Companies Intelligence Ipsen SA C H M P INC View all An oral therapy, palovarotene selectively acts on the retinoic-acid receptor gamma (RARγ). It is the first-of-its-kind medicine to seek approval for FOP treatment. Palovarotene has been analysed in a clinical programme, which included the Phase III MOVE clinical trial for FOP, for more than 15 years. In the US, palovarotene obtained orphan drug and breakthrough therapy designations from the Food and Drug Administration to potentially treat FOP. A decision on the approval by the US FDA is anticipated on 16 August 2023. The company also noted that regulatory approvals will be sought in other nations. Palovarotene obtained authorisation for usage in Canada and received provisional approval in the United Arab Emirates (UAE) as Sohonos (palovarotene capsules). Ipsen research and development executive vice-president and head Howard Mayer stated: “We believe that our clinical data provide evidence supporting the effect of palovarotene on the reduction of new, abnormal bone formation, known as heterotopic ossification, which characterises the disease. “We are therefore disappointed that the European Commission decided not to approve this treatment for patients with FOP in Europe.” A chronic condition, FOP causes flare-ups which can lead to the formation of abnormal bones.

TOKYO, June 20, 2023 /PRNewswire/ -- Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered in Tokyo, Japan (President & CEO, Eiichi Takahashi) has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of Health, Labour and Welfare (MHLW) of Japan. Jadeite Medicines has also announced initiation of a phase 3 trial in PFIC for patients in Japan. PFIC is a rare and devastating disorder affecting young children with no approved treatment in Japan. This Phase 3 trial will evaluate the efficacy and safety of an oral dosage of odevixibat in Japanese PFIC patients. Odevixibat is marketed by Ipsen Pharma (Ipsen) in the United States for the treatment of pruritus in all subtypes of PFIC and in Europe for the treatment of all subtypes of PFIC. Through the development of odevixibat, Jadeite Medicines aspires to contribute to the treatment of patients suffering from PFIC. Jadeite Medicines commits to the health and quality of life for patients through our relentless R&D in drug development in order to fulfill patient unmet needs. Progressive Familial Intrahepatic Cholestasis (PFIC) PFIC is a spectrum[1-4] of autosomal recessive genetic disorders in which cholestasis may lead to end-stage liver disease.[5] The estimated global incidence of PFIC is 1 in 100,000 live births.[5] Currently in the U.S., it is estimated that there are 500 PFIC patients who may be eligible for IBATi treatment. Subtypes PFIC1, PFIC2 and PFIC3 are the most common.[5] In addition, other rare forms of PFIC exist with varying degrees of cholestasis.[6] Patients with PFIC have impaired bile flow, or cholestasis, and the resulting bile build-up in liver cells causes liver disease and symptoms. The most debilitating symptom of PFIC is pruritus (itching), which may be so severe that it leads to skin mutilation, loss of sleep, irritability, poor attention and impaired school performance.[4] Up to 80% of PFIC patients suffer from severe pruritus, associated with abrasions, skin mutilation, hemorrhage or scarring.[7] PFIC is designated as an intractable disease (designation number 338) by the MHLW in Japan. In Japan, an estimated 100 patients suffer from PFIC. Currently there are no treatments except for symptomatic treatments in Japan and without conservative treatment patients will require surgical options including liver transplantation. Odevixibat Odevixibat is being developed by Albireo Pharma, Inc., which was acquired by Ipsen Pharmaceutical in March 2023. Albireo Pharma and Jadeite Medicines entered into an exclusive licensing agreement for the development and commercialization of odevixibat in Japan, in October 2021. Odevixibat is a once-daily, potent non-systemic ileal bile acid transport inhibitor (IBATi) that acts locally within the small intestine. Odevixibat is the first ever approved treatment for all subtypes of PFIC for patients above the age of three months in the U.S. (for the treatment of pruritis). Odevixibat is also approved by the EMA and the Medicines and Healthcare Products Regulatory Agency of the United Kingdom for all subtypes of PFIC for patients above the age of six months and is being widely commercialized in Europe. Odevixibat has been granted orphan drug designation in the U.S. and Europe. Ipsen is also filing for regulatory approval for Alagille syndrome in the U.S. based on their successful ASSERT Phase 3 clinical trial. Ipsen is also studying the use of odevixibat in other rare pediatric cholestatic liver diseases with the BOLD Phase 3 clinical trial in patients with biliary atresia where topline data from the BOLD trial is expected in 2024. Jadeite Medicines Inc. Jadeite Medicines Inc. is a biopharmaceutical company established in 2020 to fulfill the unmet medical needs of patients in Japan by introducing and developing innovative medicines from around the world. Jadeite Medicines team consists of highly experienced professionals in the field of clinical development, regulatory, CMC and business development. Jadeite Medicines continues to search for first-in-class and best-in-class medicines from around the world to create a truly innovative product portfolio. Jadeite Medicines is backed by CBC Group, Asia's largest healthcare-dedicated investment firm. For more information, visit . Ipsen Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company's research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. 1. Srivastava A J. Clin Exp Hepatol 2014;4:25-36 2. Ayoub MD. Diagnostics (Basel) 2020;10(11):907. doi:10.3390/diagnostics10110907 3. Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay (odevixibat) in Alagille syndrome. Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Alagille Syndrome | Albireo (Albireopharma.com) Last accessed: 29 December 2022 4. Sundaram S S. Liver Transpl 2017;23:96-109 doi: 10.1002/lt.24640 5. Henkel S. World J Hepatol. 2019;11(5):450-463 6. Schatz B. Hepatol Commun. 2018;2(5):504-514 7. Aldrian D. J Clin Med. 2021;10(3):481 SOURCE Jadeite Medicines Inc